testosterone undecanoate
AssetAlso Testosterone Undecanoate 750 mg, NEBIDO
Provides sustained testosterone replacement, activating androgen receptors to restore androgen-dependent functions.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- AR
- 5
- Indications
- 231
- Trials
- 2
- Developers
Indications
5Hypogonadism
Phase 3, Completed, NCT00522431, clinicaltrials.gov, 7 Oct 2026
Male hypogonadism
Phase 3, Completed, NCT01228071, clinicaltrials.gov, 7 Oct 2026
Primary hypogonadism
Phase 3, Completed, NCT00467870, clinicaltrials.gov, 7 Oct 2026
2 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials231
- Evidence for its targets3
- Competitors8
- Aging relevance1
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 10 Oct 2026, 5 sources